Cemiplimab in patients with advanced cutaneous squamous cell carcinoma: longer follow-up
Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC ) ( metastatic [ mCSCC ] or locally advanced [ laCSCC ] not amenable to curative surgery or curative radiation ) and has a safety profile consistent with other anti-PD-1 agents.
Based on initial data ( median follow-up of 9.4 months in the pivotal study ), Cemiplimab was approved for the treatment of patients with advanced CSCC.
Historical data shows median overall survival ( OS ) of approximately 15 months with conventional chemotherapy or EGFR inhibitors ( ASCO 2019, e21033 ).
Researchers have presented approximately 1-year additional follow-up from the largest prospective data set in advanced CSCC.
Patients received Cemiplimab 3 mg/kg Q2W ( Group [Gp] 1; mCSCC; Gp 2, laCSCC ) or Cemiplimab 350 mg Q3W ( Gp 3, mCSCC ).
The primary endpoint was objective response rate ( ORR; complete response + partial response ) per independent central review ( ICR ).
Data are presented per investigator review ( INV ).
193 patients were enrolled ( Gp 1, n = 59; Gp 2, n = 78; Gp 3, n = 56 ). 128 patients had received no prior anti-cancer systemic therapy, 65 patients were previously treated.
As of Oct 11, 2019 ( data cut-off ), median duration of follow-up was 15.7 months ( range: 0.6–36.1 ) among all patients; 18.5 months ( range: 1.1–36.1 ) for Gp 1, 15.5 months ( range: 0.8–35.0 ) for Gp 2, and 17.3 months ( range: 0.6–26.3 ) for Gp 3.
ORR per investigator review was 54.4% ( 95% CI: 47.1–61.6 ) for all patients; 50.8% ( 95% CI: 37.5–64.1 ) for Gp 1, 56.4% ( 95% CI: 44.7–67.6 ) for Gp 2, and 55.4% ( 95% CI: 41.5–68.7 ) for Gp 3.
ORR per investigator review was 57.8% ( 95% CI: 48.8–66.5 ) among treatment-naïve patients and 47.7% ( 95% CI: 35.1–60.5 ) among previously treated patients.
Median duration of response ( DOR ) has not been reached ( observed DOR range: 1.8–34.2 months ).
In responding patients, estimated proportion of patients with ongoing response at 24 months was 76.0% ( 95% CI: 64.1–84.4 ).
Median overall survival has not been reached. Estimated OS at 24 months was 73.3% ( 95% CI: 66.1–79.2 ).
The most common treatment-emergent adverse events ( TEAEs ) by any grade were fatigue ( 34.7% ), diarrhea ( 27.5% ), and nausea ( 23.8% ).
The most common grade 3 TEAEs or more were hypertension ( 4.7% ) and anemia and cellulitis ( each 4.1% ).
In conclusion, for patients with advanced cutaneous squamous cell carcinoma, Cemiplimab achieves ORRs, DOR and survival superior to what has been reported with other agents. ( Xagena )
Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
The FDA ( Food and Drug Administration ) has granted accelerated approval to Monjuvi ( Tafasitamab-cxix, Tafasitamab ), a CD19-directed...
Enfortumab vedotin in urothelial cancer: durable responses in patients who had previously received immunotherapy but were ineligible for Cisplatin in locally advanced or metastatic setting
The results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201, were...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
The rapid spread of Coronavirus disease 2019 ( COVID-19 ) caused by severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...
Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from TAPUR study
TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted...
Efficacy and safety of Entrectinib in patients with NTRK-fusion positive solid tumors: updated integrated analysis
NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a...
Camrelizumab is a fully humanized, monoclonal antibody against PD-1. A study has assessed the efficacy and safety of Camrelizumab plus...
Reblozyl for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia, approved in European Union
The European Commission ( EC ) has approved Reblozyl ( Luspatercept ) for the treatment of: a) adult patients with transfusion-dependent...